BIO-Europe: The CEO of Flerie, a publicly traded life sciences investment firm, discuses the firm's investment strategy and the health of biotech in the region
Ted Fjällman covers the history of the firm, and rationale for going public this year. Plus, he highlights portfolio companies such as atrogi, empros pharma, and xspray.
Brought to you by